Researchers reveal insidious role of a 'serpin' in Alzheimer's Disease

December 04, 2000

Researchers led by investigators at the Gladstone Institute of Neurological Disease and the University of California, San Francisco have discovered that the protein alpha1-antichymotrypsin can double the accumulation of Alzheimer's disease-associated amyloid plaque in the brains of mice, suggesting a possible new target for therapy in humans.

Alpha1-antichymotrypsin (ACT) is a serin protease inhibitor, or serpin, that normally prevents enzymes known as proteases from digesting proteins. Scientists have known for some time that production of ACT is increased in the brains of patients with Alzheimer's disease, where it is bound tightly to amyloid proteins in abnormal deposits called plaques. These plaques, along with tangled nerve fibers known as neurofibrillary tangles, are the main pathological hallmarks of Alzheimer's disease.

However, researchers have not known whether ACT counteracts or augments the build-up and possible toxicity of amyloid proteins. Some previous studies performed in cultured cells or with proteins themselves have found that ACT decreases the aggregation of amyloid proteins, while others have found the opposite effect or no effect at all.

The current study, conducted in genetically engineered mice, reveals that increased production of ACT in the brain strongly increases the build-up of amyloid proteins, which is associated with damage to brain cells within and around the plaques.

"We speculate that reducing or inhibiting the plaque-enhancing activity of ACT could help prevent the accumulation of plaques in the brain," says the lead author of the study, Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease at the UCSF-affiliated San Francisco General Hospital Medical Center, and Joseph B. Martin Distinguished Professor at UCSF.

"There's a sneakiness to this protein," Mucke says. "While the association of ACT with plaques has been known for more than ten years, the true nature of its activity in the brain has remained elusive for all this time. Our study now demonstrates that ACT insidiously increases the plaque burden in the aging brain."

The researchers report their findings in the December issue of American Journal of Pathology.

The discovery offers one more factor to consider in the ongoing efforts to prevent the formation of amyloid plaques in the brain. Researchers from Elan Pharmaceuticals recently reported that vaccinating mice with an amyloid beta peptide, a protein component of the amyloid plaque, prevented plaque deposition, and this finding has propelled the vaccine into human clinical trials.

Researchers still do not know whether the amyloid plaques or some of their components are responsible for the degeneration of brain cells and their connections, which underlie the cognitive decline in Alzheimer's disease, such as memory loss, anxiety, confusion and, ultimately, severe dementia.

Most likely, says Mucke, several factors contribute to both the brain damage and cognitive impairment in Alzheimer's disease. As the behavior of the transgenic mice was not tested in the investigators' mouse model, it is not clear whether the increased plaque load affected cognition.

In their study, the investigators compared mice genetically engineered to produce just amyloid proteins with those producing just ACT and those producing both amyloid proteins and ACT. Mice that expressed ACT alone did not develop amyloid plaques, while mice expressing either amyloid proteins or amyloid proteins with ACT developed typical Alzheimer's disease-like amyloid plaques.

Most important, mice producing amyloid proteins plus ACT had double the amount of plaques as mice producing amyloid proteins without ACT. This was true for mice at all ages examined, including 6-8 months (adult), 14 months (middle aged), and 20 months (old). The mice also developed swelling and abnormal twisting of the branches of the nerve cells near the plaques. These "neuritic plaques" are also found in the human disease.

The increased amyloid burden in the transgenic mice producing both amyloid protein and ACT did not increase the destruction of synaptic contacts between brain cells over that found in mice producing amyloid proteins without ACT, a finding that is consistent with previous research. Most likely, says Mucke, that destruction is caused by a soluble form of the peptide that floats between the plaques.

"The amyloid-enhancing effect of ACT we demonstrated in our study suggests that ACT might be an interesting target for therapeutic interventions," says Mucke. "Our next step will be to explore the mechanism through which this factor acts. Possibilities include that it promotes the assembly of amyloid proteins and that it prevents their degradation and clearance from the brain."
-end-
Co-investigators of the study were senior author Eliezer Masliah, MD, professor of pathology and neurosciences at University of California, San Diego; Carmela R. Abraham, PhD, professor of biochemistry and medicine at Boston University; Gui-Qiu Yu, MS, research associate at the Gladstone Institute of Neurological Disease; Lisa McConlogue, PhD a scientist at Elan Pharmaceuticals; and Edward M. Rockenstein, BS, UCSD staff research associate.

The research was supported by grants from the National Institute on Aging.

University of California - San Francisco

Related Brain Articles from Brightsurf:

Glioblastoma nanomedicine crosses into brain in mice, eradicates recurring brain cancer
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

Children with asymptomatic brain bleeds as newborns show normal brain development at age 2
A study by UNC researchers finds that neurodevelopmental scores and gray matter volumes at age two years did not differ between children who had MRI-confirmed asymptomatic subdural hemorrhages when they were neonates, compared to children with no history of subdural hemorrhage.

New model of human brain 'conversations' could inform research on brain disease, cognition
A team of Indiana University neuroscientists has built a new model of human brain networks that sheds light on how the brain functions.

Human brain size gene triggers bigger brain in monkeys
Dresden and Japanese researchers show that a human-specific gene causes a larger neocortex in the common marmoset, a non-human primate.

Unique insight into development of the human brain: Model of the early embryonic brain
Stem cell researchers from the University of Copenhagen have designed a model of an early embryonic brain.

An optical brain-to-brain interface supports information exchange for locomotion control
Chinese researchers established an optical BtBI that supports rapid information transmission for precise locomotion control, thus providing a proof-of-principle demonstration of fast BtBI for real-time behavioral control.

Transplanting human nerve cells into a mouse brain reveals how they wire into brain circuits
A team of researchers led by Pierre Vanderhaeghen and Vincent Bonin (VIB-KU Leuven, Université libre de Bruxelles and NERF) showed how human nerve cells can develop at their own pace, and form highly precise connections with the surrounding mouse brain cells.

Brain scans reveal how the human brain compensates when one hemisphere is removed
Researchers studying six adults who had one of their brain hemispheres removed during childhood to reduce epileptic seizures found that the remaining half of the brain formed unusually strong connections between different functional brain networks, which potentially help the body to function as if the brain were intact.

Alcohol byproduct contributes to brain chemistry changes in specific brain regions
Study of mouse models provides clear implications for new targets to treat alcohol use disorder and fetal alcohol syndrome.

Scientists predict the areas of the brain to stimulate transitions between different brain states
Using a computer model of the brain, Gustavo Deco, director of the Center for Brain and Cognition, and Josephine Cruzat, a member of his team, together with a group of international collaborators, have developed an innovative method published in Proceedings of the National Academy of Sciences on Sept.

Read More: Brain News and Brain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.